Caxton Corporation’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Caxton Corporation’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-15,487	Closed	-$244K	–	43
2019 Q2	$244K	Sell	15,487 -240	-2%	-$3.26K	0.28%	17
2019 Q1	$230K	Buy	15,727 +1,779	+13%	+$20.4K	0.21%	22
2018 Q4	$149K	Sell	13,948 -776	-5%	-$10.2K	0.18%	24
2018 Q3	$225K	Buy	+14,724	New	+$214K	0.21%	25
2018 Q2	–	Sell	-13,074	Closed	-$125K	–	31
2018 Q1	$125K	Buy	+13,074	New	+$141K	0.14%	20

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Caxton Corporation's DRNA Position: Q3 2019 in Review

Caxton Corporation sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2019, closing a stake of 15,487 shares — an estimated $244K sold.

Caxton Corporation first reported a position in DRNA in Q1 2018 and held it in 5 quarters. The position peaked at $244K in Q2 2019. 112 funds tracked by Wall St. Rank hold DRNA as of Q3 2019.

Caxton Corporation reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Caxton Corporation sold 15,487 Dicerna Pharmaceuticals, Inc. shares in Q3 2019, an estimated $244K.
Caxton Corporation first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 5 quarters.
Caxton Corporation's Dicerna Pharmaceuticals, Inc. position peaked at $244K in Q2 2019.
112 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2019.

Based on Caxton Corporation's 13F filing for Q3 2019, filed 14 Nov 2019.